National Research (NASDAQ:NRC) Share Price Passes Above Two Hundred Day Moving Average - What's Next?
National Research (NASDAQ:NRC) saw its share price trade above its 200-day moving average, reaching $17.59 before settling at $17.34. Despite this, analyst sentiment remains negative, with a "Sell" rating and a recent downgrade from Weiss Ratings. Concerns about the company's financial health include a high dividend payout ratio, weak liquidity, and significant leverage.
National Research (NASDAQ:NRC) Breaks Key Trendline Amid Nasdaq Index Momentum
National Research (NASDAQ:NRC) is gaining attention as its share price has crossed key levels, driven by both institutional investment activity and its strong position in healthcare analytics within the broader Nasdaq index trends. The article indicates that NRC's valuation is influenced by operational performance and healthcare technology, while its stock movement reflects healthcare sector trends and the adoption of its analytics platform.
National Research Corp (NRC) Stock Price Quote Today & Current Price Chart
This article provides the current stock price quote and chart for National Research Corp (NRC). It also mentions that online trading is available through the Smart Investment App offered by Capital.com.
National Research Corp (NRC) Stock Price Quote Today & Current Price Chart
This article provides the stock price quote and current price chart for National Research Corp (NRC). It also mentions that Capital.com offers online trading with a smart investment app. The content is very minimal, essentially just stating what is being offered.
National Research Corp (NRC) Stock Price Quote Today & Current Price Chart
This page provides the current stock price quote and chart for National Research Corp (NRC). It also mentions that the content is provided by Capital.com, an online trading platform.
National Research Corp (NRC) Stock Price Quote Today & Current Price Chart | Capital.com Australia
This page on Capital.com Australia provides current trading information for National Research Corp (NRC) stock as a Contract for Difference (CFD). It details trading conditions, key financial stats like previous close, open, and 1-year change, and lists related articles and market reviews. The platform highlights the high-risk nature of CFD trading.
National Research Corporation (NASDAQ:NRC) Plans $0.16 Quarterly Dividend
National Research Corporation (NASDAQ:NRC) announced a quarterly dividend of $0.16 per share, payable on April 10th to shareholders of record on March 27th, with an ex-dividend date of March 27th. This dividend represents an annual yield of 3.7%, though the company's dividend growth has been modest at 0.2% annually over the past three years. The healthcare analytics firm reported recent quarterly EPS of $0.16 on $35.19 million in revenue, trading near a market cap of $396.8 million.
If You Invested $1,000 in National Resh Corp (NRC)
This article analyzes the historical performance of investing $1,000 in National Research Corporation (NRC) over various periods, showing returns for one, five, and ten years. It also provides a detailed overview of NRC Health, highlighting its focus on healthcare experience improvement, market research, and financial reporting. The analysis includes year-by-year stock performance comparisons against the S&P 500 and answers frequently asked questions about NRC investments.
Piedmont Names NRC Health as a Strategic Experience Partner to Support Mission-Driven Growth
Piedmont, a Georgia-based healthcare system serving 4.5 million patients annually across 27 hospitals and 2,000 locations, has partnered with NRC Health as its strategic experience management partner. This collaboration aims to enhance patient, family, employee, and consumer experiences by leveraging NRC Health's Patient Experience, Leader Rounding, and Market Insights solutions, alongside consulting services. The partnership seeks to unify experience data, strengthen caregiver engagement, and integrate patient feedback into strategic decisions.
National Research (NASDAQ:NRC) Trading Move Aligns With Nasdaq Index Fund
National Research Corporation (NASDAQ:NRC) has garnered market attention after its stock moved above a significant long-term moving average, indicating a shift in trading momentum. This positive movement, coupled with institutional activity and the company's healthcare analytics positioning, aligns with current Nasdaq index fund trends. The company uses cloud-based platforms to gather patient and workforce experience data for healthcare providers.
NRC (NRC) EVP Jason Rau granted 60,000 restricted stock units
Jason Rau, Executive Vice President at National Research Corp (NRC), was granted 60,000 restricted shares of common stock as part of the company's 2025 Omnibus Incentive Plan. These shares were awarded at no cash cost and will vest in three equal installments on January 1, 2027, 2028, and 2029. This transaction is a compensation-related equity grant rather than an open-market purchase, and following the award, Rau directly holds 60,000 shares.
What Makes National Research Corporation (NRC) a Good Investment Choice?
Long Cast Advisers, an investment firm, highlighted National Research Corporation (NASDAQ: NRC) in its Q4 2025 investor letter, noting it as a new position and a significant contributor. Despite the firm's reservations about the healthcare consulting business model, they see value in NRC's financial metrics, including its $430 million market capitalization and 13x multiple against annualized EBITDA. The article also mentions NRC's recent strong stock performance, with a 36.59% one-month return and an 11.26% gain over the past 52 weeks.
NRC SEC Filings - National Resh Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for National Research Corporation (NRC) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading information. It highlights recent filings with AI-generated summaries, such as executive stock grants, option exercises, and the latest quarterly earnings report for Q3 2025. The platform aims to simplify access and understanding of regulatory documents for investors.
NRC SEC Filings - National Resh Corp 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for National Research Corporation (NRC) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-powered summaries. Recent filings highlight the appointment of a new CFO with details on compensation and the Q2-25 10-Q report, which revealed a significant profit decline, increased leverage, and changes in leadership. The platform aims to simplify the understanding of these regulatory documents for investors and traders.
National Research Shares Cross 200-Day Average, Analysts Warn of Sell Signal
Shares of National Research Corporation (NASDAQ:NRC), a healthcare analytics firm, have crossed above their 200-day moving average, a technical indicator that some analysts view as a potential sell signal. One analyst has downgraded the stock to a 'sell' rating due to valuation and performance concerns, despite the 200-day moving average typically being seen as a bullish signal. The stock's current trading at $14.97, along with its P/E ratio of 29.94 and high debt-to-equity ratio of 5.36, contribute to these concerns.
National Research (NASDAQ:NRC) Shares Pass Above 200 Day Moving Average - Time to Sell?
National Research (NASDAQ:NRC) shares recently crossed above their 200-day moving average, trading as high as $15.92, though they closed at $14.97. Despite this, Weiss Ratings downgraded the stock to "sell" due to concerns about its financial health, including a high payout ratio of 128%, weak liquidity, and significant debt. Institutional investors have made varied adjustments to their holdings in NRC, which operates as NRC Health, specializing in healthcare analytics.
National Research Hits Record Recurring Contract Value Milestone
NRC Health reported a record Total Recurring Contract Value (RCV) of over $152 million, marking a 6% increase from the end of 2025 and 13% year-over-year growth. Despite this milestone, TipRanks' AI Analyst, Spark, rates NRC as Neutral, citing deteriorating financial performance, elevated leverage, and bearish technicals. NRC Health is a healthcare technology company providing solutions to improve healthcare experience.
National Research Corporation (NRC) Approves $60 Million Stock B
National Research Corporation (NRC) has approved a stock repurchase program of up to $60 million, aiming to enhance shareholder value through March 31, 2028. The company, which provides healthcare analytics, exhibits strong gross margins but faces challenges with a high debt-to-equity ratio and potential liquidity issues. Despite a premium valuation and high volatility, insider activity shows positive sentiment, and the buyback is expected to provide a short-term boost.
NRC falls after announcing $60 million share repurchase program
NRC Group Holdings Inc. stock fell after the company announced a $60 million share repurchase program. The repurchases will be made using available cash and cash generated from operations, and will occur at management's discretion. The program does not obligate the company to acquire any specific number of shares.
Healthcare data firm NRC Health earmarks $60M to buy back stock
NRC Health (NASDAQ: NRC) announced that its Board of Directors has authorized a share repurchase program of up to $60 million of its common stock, effective through March 31, 2028. The company plans to repurchase shares through various means, including open market and privately negotiated transactions, in compliance with SEC regulations. This move aims to return value to shareholders and will be executed at NRC Health's discretion based on market conditions and other factors.
National Research Corporation announces an Equity Buyback for $60 million worth of its shares.
National Research Corporation (NRC) has authorized a share repurchase program worth up to $60 million. This program will be active until March 31, 2028, allowing the company to buy back its own shares from the market. The announcement was made on March 9, 2026.
Price-Driven Insight from (NRC) for Rule-Based Strategy
This article provides a price-driven insight for National Research Corporation (NYSE: NRC), highlighting strong sentiment across all horizons and a mid-channel oscillation pattern. It presents an exceptional risk-reward short setup and outlines three distinct AI-generated trading strategies tailored for different risk profiles: a position trading strategy, a momentum breakout strategy, and a risk hedging strategy, complete with entry, target, and stop-loss levels.
National Research Corporation (NRC) Hits Record High in Recurring Contract Value
National Research Corporation (NRC) has achieved a record Total Recurring Contract Value (TRCV) exceeding $152 million as of March 4, 2026. Despite this milestone, the company faces financial challenges including modest revenue growth, declining profitability, and high debt levels, leading to potential liquidity concerns. While the stock appears to trade at a premium, investors are advised to exercise cautious optimism due to mixed financial indicators and various risk factors.
National Research 2025 10-K: Revenue $137.4M, EPS $0.50
National Research (NRC) reported 2025 revenues of $137.4 million and diluted EPS of $0.50, both declining from 2024 due to reduced recurring revenue from existing customers. Despite a fall in operating and net income, the company anticipates a recovery in revenue and cash generation for 2026, driven by operational initiatives and new product launches.
National Research Corporation (NRC) Hits Record High in Recurring Contract Value
National Research Corporation (NRC) has achieved a record-high Total Recurring Contract Value (TRCV) of over $152 million, indicating expected revenue from renewable contracts. Despite this milestone, the company faces financial challenges including modest revenue growth, declining operating margins, high debt, and potential liquidity concerns, placing it in a "grey area" for financial stress. Investors are advised to exercise cautious optimism due to mixed financial indicators and various risk factors.
$152M in recurring healthcare contracts puts NRC Health at new high
NRC Health (NASDAQ: NRC) announced that its Total Recurring Contract Value (TRCV) has reached an all-time high of over $152 million as of March 4, 2026. This represents a 6% increase from the end of 2025 and a 13% year-over-year growth. The company attributes this milestone to the strong confidence from its health system partners and the expanding long-term relationships, emphasizing the critical role of its platform in healthcare decision-making.
NRC Health (NASDAQ: NRC) hits $152M TRCV with 13% YoY growth
NRC Health announced its Total Recurring Contract Value (TRCV) has reached an all-time high of over $152 million as of March 4, 2026, marking a 13% year-over-year increase. This growth is attributed to strong, long-term relationships with health system partners and reflects projected revenue from renewable contracts over the next 12 months. The company emphasized that this milestone does not represent complete financial results for the quarter ending March 31, 2026.
National Research Corporation (NASDAQ:NRC) Sees Significant Growth in Short Interest
National Research Corporation (NASDAQ:NRC) has experienced a significant increase in short interest, with a 33.7% jump to 471,736 shares as of February 13th. This represents about 2.1% of the stock, leading to a short-interest ratio of 2.7 days. Despite a high dividend yield of approximately 4.6%, the company's dividend payout ratio is stretched at 128%, and institutional investors hold 47.26% of the stock.
National Research Corporation Sees Spike in Short Interest
National Research Corporation (NASDAQ:NRC) experienced a significant 33.7% increase in short interest during February, reaching 471,736 shares. This suggests some investor caution regarding the healthcare analytics firm's near-term prospects. However, the relatively low short-interest ratio indicates that the impact on the share price might be limited.
NRC Should I Buy
An analysis by Intellectia AI suggests that National Research Corp (NRC) is not a strong buy for long-term beginner investors due to weak financial performance in Q4 2025, bearish technical indicators, and a lack of positive catalysts. Despite insider buying, it's recommended to hold off on investment until stronger signals or improved fundamentals emerge. The company saw significant year-over-year drops in revenue, net income, and EPS in Q4 2025, with no recent analyst rating updates.
National Research Corporation (NRC) Stock Analysis: Balancing Robust ROE And Dividend Yield Amidst Revenue Challenges
National Research Corporation (NRC) is a healthcare information services provider with a market capitalization of $292.96 million. Despite facing a revenue contraction of 4.60% and stock volatility, the company shows a strong Return on Equity (ROE) of 51.24% and an attractive dividend yield of 4.33%. However, its 104.00% payout ratio raises concerns about dividend sustainability given current earnings challenges.
NRC (NRC) CFO Harrison purchases 8,000 shares in open-market trade
Shane R. Harrison, EVP and CFO of National Research Corp (NRC), purchased 8,000 shares of company common stock on February 17, 2026, at a weighted average price of $12.2703 per share through an IRA account. This transaction reflects an indirect ownership increase, while Harrison also maintains 150,729 shares in direct ownership. The Form 4 filing details this open-market acquisition and the company's current stock data.
National Research Corp (NRC) director receives 8,819 stock options grant
National Research Corp (NRC) director Parul Bhandari was granted 8,819 stock options on January 22, 2026, as compensation for participating in board meetings. The options have an exercise price of $22.01 per share and expire on January 22, 2036. This grant was made under the company’s 2025 Omnibus Incentive Plan.
NRC | National Research Corporation Common Financials - Income Statement
This page provides financial and other related data for National Research Corporation (NRC). It highlights information regarding insider trading, institutional holdings, corporate lobbying, government contracts, and analyst ratings, along with key financial statements like the Income Statement. The article also describes NRC's business as a provider of analytics and insights for healthcare organizations.
(NRC) as a Liquidity Pulse for Institutional Tactics
This article provides an AI-driven analysis of National Research Corporation (NYSE: NRC), highlighting weak near and mid-term sentiment, despite a strong long-term outlook. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, including support and resistance levels. The analysis emphasizes an exceptional risk-reward setup targeting an 18.8% gain for long-term positions.
National Research: Q4 Earnings Snapshot
National Research Corp. (NRC) reported Q4 earnings of $1.8 million, or 8 cents per share, with adjusted earnings of 16 cents per share. The company's revenue for the quarter was $35.2 million. For the full year, NRC posted a profit of $11.6 million, or 50 cents per share, on revenue of $137.4 million.
How NRC Health's patient experience tech rose to #1 in 2026 KLAS
NRC Health has been awarded the 2026 Best in KLAS Award for Healthcare Experience Management for the third time in four years, recognizing its leadership in humanizing healthcare through technology and data-driven insights. The company designs solutions with partners to improve patient and employee experiences, offering a 360-degree view for informed decision-making. KLAS CEO Adam Gale emphasized that the award signifies vendor excellence in partnering with healthcare organizations to improve patient care and outcomes.
(NRC) Risk Channels and Responsive Allocation
This article provides an analysis of National Research Corporation (NYSE: NRC), highlighting weak near-term sentiment but strong long-term prospects. It outlines various AI-generated trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, based on multi-timeframe signal analysis. The report also details current support and resistance levels and an exceptional risk-reward setup for the stock.
National Research (NRC) Margin Compression Reinforces Bearish Earnings Narratives
National Research (NRC) recently reported its Q3 FY 2025 earnings, revealing revenue of US$34.6 million and EPS of US$0.18. The company has experienced a long run of declining earnings and compressing net profit margins, now at 11.6% compared to 18.8% the previous year, reinforcing bearish narratives despite remaining profitable in Q3. Its valuation sits between industry and peer averages, with the share price currently above a DCF fair value estimate.
National Research Q4 2025 Earnings Call Transcript
National Research (NRC Health) reported Q4 2025 revenue of $35.2 million, a 5% year-over-year decrease, and full-year revenue of $137.4 million, down 4% from 2024. Despite the revenue decline, Total Recurring Contract Value (TRCV) grew 8% year-over-year to $144.1 million, marking the fifth consecutive quarter of sequential TRCV growth. The company maintained strong profitability with a full-year adjusted EBITDA of $40.2 million (29% margin) and highlighted successful go-to-market strategies, strengthened customer retention, and investments in enablement solutions and AI-powered product innovation as key growth catalysts for 2026.
NRC 2025 Earnings Report: $11.6M Annual Profit | Healthcare Advisor - News and Statistics
National Research Corp. (NRC) reported a fourth-quarter profit of $1.8 million, or 8 cents per share, with adjusted earnings of 16 cents per share. The company, an advisor to healthcare providers, posted fourth-quarter revenue of $35.2 million. For the full 2025 fiscal year, NRC achieved a profit of $11.6 million, or 50 cents per share, on annual revenue of $137.4 million.
National Research: Fourth Quarter Earnings Overview
National Research Corp. announced its financial results for the fourth quarter, reporting a net income of $1.8 million and adjusted earnings of $0.16 per share on revenues of $35.2 million. For the full fiscal year, the company achieved a profit of $11.6 million and total revenues of $137.4 million, confirming its role as a healthcare consultant.
National Research Declares Quarterly Dividend of $0.16
National Research (NRC) has declared a quarterly dividend of $0.16 per share, maintaining consistency with previous distributions and signaling confidence in its financial health. This dividend offers a forward yield of 2.92%, making it attractive to investors seeking stable returns. The payment is scheduled for April 10, with record and ex-dividend dates on March 27.
National Research: Fourth Quarter Earnings Overview
National Research Corp. has announced its financial results for the fourth quarter, reporting a net income of $1.8 million and adjusted earnings of $0.16 per share on revenue of $35.2 million. For the full fiscal year, the company posted a profit of $11.6 million and annual revenue of $137.4 million. National Research Corp. provides consulting services to healthcare organizations.
National Research: Fourth Quarter Earnings Overview
National Research Corp. announced its financial results for the fourth quarter, reporting a net income of $1.8 million and earnings of $0.08 per share, or $0.16 per share when adjusted for one-time expenses. The company's revenue for the quarter reached $35.2 million, contributing to a full fiscal year profit of $11.6 million on $137.4 million in revenue. National Research Corp. provides consulting services to healthcare organizations.
Top Research Reports for Meta, Palantir and Amphenol
This article highlights key research reports for major stocks including Meta Platforms (META), Palantir Technologies (PLTR), and Amphenol Corp. (APH), as well as National Research Corp. (NRC). It details the financial performance and analyst sentiment for each company, noting strengths like user growth for Meta and AI strategy for Palantir, alongside challenges like competition and economic uncertainty. The report also briefly covers other stocks and Zacks' "Ahead of Wall Street" daily article.
National Research Corporation (NRC): Investor Outlook on a Healthcare Data Pioneer with a Strong Return on Equity
National Research Corporation (NRC), a healthcare information services company, shows a strong return on equity (ROE) of 66.87%, despite a negative revenue growth of -3.40%. The company, valued at $456.89 million, specializes in analytics for patient and employee experiences and recently introduced an advanced AI engine, Huey AI. Trading at $19.81, NRC offers a dividend yield of 2.62% and a strong free cash flow, but lacks traditional valuation metrics and analyst coverage.
NRC: Integrating NPS and HCAHPS with timely, focused action accelerates patient experience gains
This article highlights how integrating NPS and HCAHPS data with timely feedback and demographic insights can improve patient experience and financial outcomes. The key is to focus on long-term trends, prioritize high-impact behaviors, and foster supportive leadership, as demonstrated by National Research Corporation (NRC). This approach helps accelerate gains in patient satisfaction.
National Research (NASDAQ:NRC) Stock Price Passes Above 200-Day Moving Average - Time to Sell?
National Research (NASDAQ:NRC) saw its stock price rise above its 200-day moving average to $21.07, despite trading down 4.3% on Friday morning. The company, which has a market cap of $477.5M and high leverage, recently had its rating upgraded by Weiss Ratings from "sell" to "hold." Institutional investors have been adjusting their stakes in NRC, with several increasing their holdings in recent quarters.
(NRC) Movement as an Input in Quant Signal Sets
This article from Stock Traders Daily discusses how the movement of National Research Corporation (NYSE: NRC) is used as an input in quantitative signal sets. It highlights strong sentiment across all time horizons supporting an overweight bias for NRC, even with elevated downside risk. The analysis includes AI-generated trading strategies for different risk profiles and provides specific entry zones, targets, and stop losses.
